Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2006-10-18
2011-11-22
Azpuru, Carlos (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
08062657
ABSTRACT:
Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
REFERENCES:
patent: 4521210 (1985-06-01), Wong
patent: 4853224 (1989-08-01), Wong
patent: 4997652 (1991-03-01), Wong
patent: 5164188 (1992-11-01), Wong
patent: 5336767 (1994-08-01), Della Valle et al.
patent: 5443505 (1995-08-01), Wong
patent: 5501856 (1996-03-01), Ohtori
patent: 5540930 (1996-07-01), Guy et al.
patent: 5632984 (1997-05-01), Wong
patent: 5646136 (1997-07-01), Petrow et al.
patent: 5766242 (1998-06-01), Wong
patent: 5770589 (1998-06-01), Billson et al.
patent: 5824072 (1998-10-01), Wong
patent: 5869079 (1999-02-01), Wong
patent: 6074661 (2000-06-01), Olejnik
patent: 6331313 (2001-12-01), Wong
patent: 6369116 (2002-04-01), Wong
patent: 6699493 (2004-03-01), Wong
patent: 6726918 (2004-04-01), Wong
patent: 2002/0182185 (2002-12-01), Wong
patent: 2003/0060763 (2003-03-01), Penfold et al.
patent: 2004/0171598 (2004-09-01), Bingaman
patent: 2005/0101582 (2005-05-01), Lyons
patent: 2005/0244474 (2005-11-01), Huang et al.
patent: 0244178 (1987-11-01), None
patent: 0 661 055 (1995-07-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 2004/050065 (2004-06-01), None
patent: WO 2005/072701 (2005-08-01), None
patent: WO 2005/107727 (2005-11-01), None
Edelman et al., Exp. Eye Res. 80:249-258 (2005).
Heller, Biodegradable Polymers in Controlled Drug Delivery, In: CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, CRC Press, Boca Raton, FL 1987, pp. 39-90.
Hudson, Henry L., Retinal Physician Jul. 2005 (www.retinalphysician.com/article.aspx?article=100098).
USP 23; NF 18 (1995) pp. 1790-1798.
U.S. Appl. No. 60/728,209, filed Oct. 18, 2006, Edelman.
Fiahlo, Silvia Ligorio et al.,Manufacturing Techniques of Biodegradable Implants Intended for intraocular Application, Drug Delivery, Academic Press, Orlando, FL, vol. 12, No. 2, Apr. 2005, pp. 109-116.
Missel, P.J. et al.,Dissolution of anecortave acetate in a cylindrical flow cell: re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs, Pharmaceutical Development and Technology, vol. 9, No. 4, 2004, pp. 453-459.
Wu, W. et al.,Intravitreally injectable poly(D,L-lactide)microspheres containing deamethasone acetate for sustained release, Biosciences Information Service, Philadelphia, PA, Oct. 2001, vol. 36, No. 10, pp. 766-770.
Stokes et al, “Altered Peripheral Sensitivity to Glucocorticoids in Primary Open-Angle Glaucoma”, Invest.Ophthalmol Vis Sci. 44, 5163-5167, 2003.
Edelman Jeffrey L.
Harrison Kelly M.
Allergan Inc.
Allergan, Inc.
Azpuru Carlos
Condino Debra D.
German Joel B.
LandOfFree
Ocular therapy using glucocorticoid derivatives selectively... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ocular therapy using glucocorticoid derivatives selectively..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular therapy using glucocorticoid derivatives selectively... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311051